Biogen 주식 가격. 0R1B - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

가격

277.67

매수가

0.00

매도가

0.00

거래량

4,617

0.00 일간 변동폭 0.00

277.67 52주 범위 277.67

market_cap

40.462B

전일 종가

277.67

개장가

최근 거래 시간

142.68

(O)

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

3,536

발행 주식

145,719,000

배당수익률

주가수익률

12.83

주당순이익(EPS)

11.2

매출

9.68B

순이익

1.63B

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

www.biogen.com

본부

Wilmington, Delaware, USA

설립됨

Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the 런던증권거래소 with ticker 0R1B. The last closing price for Biogen was US$277.67. Over the last year, Biogen shares have traded in a share price range of US$ 277.67 to US$ 277.67.

Biogen currently has 145,719,000 shares in issue. The market capitalisation of Biogen is US$40.46 billion. Biogen has a price to earnings ratio (PE ratio) of 12.83.

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients Global...

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare...

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE...

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Once every four weeks maintenance...

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA Applications are based on data from the DEVOTE study, which...

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus...

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov...

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD...

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and...

기간	시가	고가	저가	평균 일일 거래량	VWAP
1	277.67	277.67	277.67	2772	277.67	DE
4	277.67	277.67	277.67	3753	277.67	DE
12	277.67	277.67	277.67	3536	277.67	DE
26	277.67	277.67	277.67	4166	277.67	DE
52	277.67	277.67	277.67	3685	277.67	DE
156	277.67	277.67	277.67	4466	277.67	DE
260	277.67	277.67	277.67	4017	277.67	DE

0R1B - Frequently Asked Questions (FAQ)

What is the current Biogen share price?

The current share price of Biogen is US$ 277.67

How many Biogen shares are in issue?

Biogen has 145,719,000 shares in issue

What is the market cap of Biogen?

The market capitalisation of Biogen is USD 40.46B

What is the 1 year trading range for Biogen share price?

Biogen has traded in the range of US$ 277.67 to US$ 277.67 during the past year

What is the PE ratio of Biogen?

The price to earnings ratio of Biogen is 12.83

What is the cash to sales ratio of Biogen?

The cash to sales ratio of Biogen is 2.16

What is the reporting currency for Biogen?

Biogen reports financial results in USD

What is the latest annual turnover for Biogen?

The latest annual turnover of Biogen is USD 9.68B

What is the latest annual profit for Biogen?

The latest annual profit of Biogen is USD 1.63B

What is the registered address of Biogen?

The registered address for Biogen is 3411 SILVERSIDE ROAD TATNALL, BUILDING #104, NEW CASTLE, WILMINGTON, DELAWARE, 19810

What is the Biogen website address?

The website address for Biogen is www.biogen.com

Which industry sector does Biogen operate in?

Biogen operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
GCMGcm Resources Plc	2.50p (36.99%)	19.2M
CRTCare Reit Plc	108.60p (33.58%)	85.61M
DELTDeltic Energy Plc	3.875p (19.23%)	3.08M
SOLISolid State Plc	202.50p (15.71%)	463.14k
PHEPowerhouse Energy Group Plc	0.75p (15.38%)	36.4M
SNGSynairgen Plc	1.20p (-39.85%)	6.45M
HEMOHemogenyx Pharmaceuticals Plc	195.00p (-36.17%)	712.91k
THRUThruvision Group Plc	1.60p (-28.89%)	425.77k
HVTHeavitree Brewery Plc	200.00p (-27.27%)	9.43k
ADFFacilities By Adf Plc	20.50p (-26.79%)	3.62M
VELAVela Technologies Plc	0.003p (7.14%)	2.23B
PREMPremier African Minerals Limited	0.0107p (-13.71%)	1.4B
UKOGUk Oil & Gas Plc	0.01p (-9.09%)	363.68M
CORCorpus Resources Plc	0.015p (3.45%)	304.93M
LLOYLloyds Banking Group Plc	67.16p (-2.92%)	197.24M